Drugmakers Including Bayer AG, AstraZeneca PLC and Johnson & Johnson Pool R&D in $265 Million EU Project

Published: Feb 11, 2013

Seven European drugmakers are to pool their research efforts with academic scientists and smaller companies in a new 196 million euros ($265 million) project designed to find tomorrow's medicines. The project, backed by the European Union, is the latest example of the drugs industry exploring ways to share early-stage research, effectively taking lessons from the kind of open innovation that gave the world Linux software. As part of the European Lead Factory scheme, pharmaceutical companies will contribute at least 300,000 chemical compounds from their in-house collections and a further 200,000 will be developed jointly by academia and small firms. The idea is to use crowdsourcing to generate novel ideas for tackling certain diseases, which can then be tested by screening compounds using shared pharmaceutical industry know-how. "It's a big change for companies because their compound libraries have usually been kept very secret," said Ton Rijnders, scientific director of Dutch non-profit group TI Pharma, who is helping to run the project. "They are doing this because it is cheaper than building ever larger libraries on their own - and partnering with academics gives them access to innovative ideas." The seven drugmakers involved in the scheme are Bayer , AstraZeneca, Sanofi, Lundbeck , Merck KGaA, UCB and Janssen, the European arm of Johnson & Johnson. Academic partners include universities in Germany, Britain, the Netherlands and Denmark.

Back to news